Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
Changes in microbiome have been reported recently in psoriasis lesions compared to healthy
surround skin. Preliminary data showed that systemic treatments of psoriasis induce
modification of the skin microbiome that becomes similar to healthy individuals after
successful treatment. The causative role of microbiome in psoriasis remains in debate. The
modification of skin microbiome is suspected to be able to activate the innate immune
response, namely natural killers (NKs) and immune lymphoid cells (ILCs). Three types of ILCs
have been reported. ILC1 (immune lymphoid cells1) that trigger a Th1 response, ILC2 (immune
lymphoid cells 2) that stimulate Th2 response and ILC3 (immune lymphoid cells 3) that induce
Th17 response. Interestingly, ILC2 have been reported to be increased in atopic dermatitis
while ILC3 are increased in psoriasis.